Compare MARA & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MARA | AMRX |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | N/A | 8500 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | 2010 | 2018 |
| Metric | MARA | AMRX |
|---|---|---|
| Price | $13.80 | $12.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $17.85 | $15.60 |
| AVG Volume (30 Days) | ★ 38.4M | 1.4M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $907,093,000.00 | N/A |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | $13.31 | $7.13 |
| P/E Ratio | ★ N/A | $65.29 |
| Revenue Growth | ★ 38.20 | N/A |
| 52 Week Low | $6.66 | $7.07 |
| 52 Week High | $23.45 | $15.42 |
| Indicator | MARA | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.17 | 46.41 |
| Support Level | $9.65 | $11.60 |
| Resistance Level | $16.63 | $12.85 |
| Average True Range (ATR) | 0.90 | 0.37 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 87.64 | 31.49 |
MARA Holdings Inc leverages digital asset computing to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value. The company also offers technology solutions to optimize data center operations, including next-generation liquid immersion cooling and firmware for Bitcoin miners. It is focused on computing for, acquiring, and holding digital assets as a long-term investment.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.